Literature DB >> 8620924

Differential binding of apolipoprotein E isoforms to tau and other cytoskeletal proteins.

L M Fleming1, K H Weisgraber, W J Strittmatter, J C Troncoso, G V Johnson.   

Abstract

The apolipoprotein E4 (apoE4) gene dose is a major risk factor for late-onset and sporadic Alzheimer's disease with 50% of homozygous patients developing the disease by age 70. Previous studies have shown localization of apoE to the cytoplasm of certain neurons within the brain. In addition, apoE3, but not apoE4, forms SDS-stable complexes with the microtubule-associated proteins tau and MAP-2. To extend these studies and quantitate the association of apoE with other proteins, the association of apoE3 and apoE4 with several cytoskeletal proteins was examined using both gel shift and overlay assays. In the gel shift assay, apoE3 formed SDS-stable complexes with the longest isoform of human recombinant tau (T4L), the shortest isoform of human recombinant tau (T3), and the 160-kDa neurofilament protein (NFM). ApoE4 did not bind T3, T4L, or NFM in this assay. The association of apoE3 and apoE4 with T4L, actin, or tubulin was further examined in an overlay assay with known amounts of the cytoskeletal proteins slot-blotted onto nitrocellulose and incubated in 0.15 microM (5 microg/ml) apoE3 or apoE4. In this assay, apoE3 and apoE4 bound T4L and tubulin equally well. In contrast, apoE3 bound actin with a significantly greater affinity than did apoE4. These results indicate that apoE isoforms interact with cytoskeletal proteins with at least two different binding affinities. The more avid interaction results in the formation of complexes which are SDS stable and occurs almost exclusively with apoE3, while the other interactions between apoE and cytoskeletal proteins are specific for apoE3.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8620924     DOI: 10.1006/exnr.1996.0064

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  17 in total

Review 1.  Changes in the ageing brain in health and disease.

Authors:  B H Anderton
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-12-29       Impact factor: 6.237

Review 2.  Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration.

Authors:  M L Billingsley; R L Kincaid
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

3.  Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.

Authors:  Yuetiva Deming; Zeran Li; Manav Kapoor; Oscar Harari; Jorge L Del-Aguila; Kathleen Black; David Carrell; Yefei Cai; Maria Victoria Fernandez; John Budde; Shengmei Ma; Benjamin Saef; Bill Howells; Kuan-Lin Huang; Sarah Bertelsen; Anne M Fagan; David M Holtzman; John C Morris; Sungeun Kim; Andrew J Saykin; Philip L De Jager; Marilyn Albert; Abhay Moghekar; Richard O'Brien; Matthias Riemenschneider; Ronald C Petersen; Kaj Blennow; Henrik Zetterberg; Lennart Minthon; Vivianna M Van Deerlin; Virginia Man-Yee Lee; Leslie M Shaw; John Q Trojanowski; Gerard Schellenberg; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Elaine R Peskind; Ge Li; Antonio F Di Narzo; John S K Kauwe; Alison M Goate; Carlos Cruchaga
Journal:  Acta Neuropathol       Date:  2017-02-28       Impact factor: 17.088

4.  Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology.

Authors:  Shan Liu; Ariel Breitbart; Yanjie Sun; Pankaj D Mehta; Allal Boutajangout; Henrieta Scholtzova; Thomas Wisniewski
Journal:  J Neurochem       Date:  2013-11-06       Impact factor: 5.372

5.  Modulation of tau phosphorylation and intracellular localization by cellular stress.

Authors:  S M Jenkins; M Zinnerman; C Garner; G V Johnson
Journal:  Biochem J       Date:  2000-01-15       Impact factor: 3.857

Review 6.  Interaction of apolipoprotein E epsilon 4 with other genetic and non-genetic risk factors in late onset Alzheimer disease: problems facing the investigator.

Authors:  R Katzman; D Kang; R Thomas
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

7.  APOEε2 is associated with milder clinical and pathological Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Jing Qian; Sarah E Monsell; Rebecca A Betensky; Bradley T Hyman
Journal:  Ann Neurol       Date:  2015-06       Impact factor: 10.422

Review 8.  The many faces of tau.

Authors:  Meaghan Morris; Sumihiro Maeda; Keith Vossel; Lennart Mucke
Journal:  Neuron       Date:  2011-05-12       Impact factor: 17.173

Review 9.  Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight.

Authors:  Yang Shi; David M Holtzman
Journal:  Nat Rev Immunol       Date:  2018-12       Impact factor: 53.106

10.  Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease.

Authors:  Gustavo Basurto-Islas; Jose Luna-Muñoz; Angela L Guillozet-Bongaarts; Lester I Binder; Raul Mena; Francisco García-Sierra
Journal:  J Neuropathol Exp Neurol       Date:  2008-05       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.